Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)

Number of survivors at 2 years

for cohorts 1 and 2

Time frame: At 2 years

Number of survivors at 5 years

for cohorts 1 and 2

Time frame: 5 years

HTLV-1 proviral load

for cohorts 1 and 2

Time frame: day 1

viral integration profile

for cohorts 1 and 2

Time frame: day 1

lymphocyte phenotyping of tumor cells

for cohorts 1 and 2

Time frame: day 1

genetic analysis of tumor cells by Next-generation sequencing (NGS)

for cohorts 1 and 2

Time frame: day 1

number of patients with HTLV-1-related hematological disorders

for cohort 1

Time frame: day 1

number of patients with HTLV-1-related extra-hematological disorders

for cohort 1

Time frame: day 1

types of ATL

According the Shimoyama classification (smoldering, chronic, Acute and Lymphoma) for cohort 1

Time frame: day 1

Treatment lines

Chemotherapy type, number of Chemotherapy cycles, efficacity of Chemotherapy : Number of complete remissions following treatment : for cohort 1

Time frame: during 5 years

Response to induction therapy

according to established response criteria for ATL for cohort 1

Time frame: during 5 years

Progression free survival (PFS)

for cohort 1

Time frame: during 5 years

relapse-related mortality

for cohort 1

Time frame: during 5 years

chemotherapy-related mortality

for cohort 1

Time frame: during 5 years

transplant-related mortality

for cohort 1

Time frame: during 5 years

Number of serious adverse events according to WHO classification related to treatment received

for cohort 1

Time frame: during 5 years

Allograft-specific characteristic

(donor type, conditioning type, engraftment, graft-related mortality) for cohort 1

Time frame: during 5 years

number of progression to ATL

Time frame: at 2 years

Number of progression to ATL

Time frame: At 5 years

number of patients with HTLV-1-related extrahematological disorders

Time frame: during 5 years

Number of patients with corticotherapy for extrahematological complications

Dose of corticotherapy for extrahematological complications, number of days with corticotherapy for extrahematological complications

Time frame: during 5 years

Number of Serious adverse events according to WHO classification related to treatment received

Time frame: during 5 years